Merz bids above Valeant for Obagi's skin products
This article was originally published in Scrip
Executive Summary
Merz Pharma Group apparently was blind-sided by Valeant Pharmaceuticals' planned acquisition of Obagi Medical Products, so Merz went directly to Obagi's board of directors with a $22 per share offer that beats Valeant's $19.75 bid for skin care-focused Obagi.